(Q36046266)

11 August 2017

1 reference

title

Management of bone metastases in breast cancer (English)

1 reference

11 August 2017

1 reference

Allan Lipton

1

1 reference

11 August 2017

publication date

1 March 2005

1 reference

Current Treatment Options in Oncology

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

161-171

1 reference

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

11 August 2017

cites work

1 reference

12 December 2020

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

12 December 2020

Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid

1 reference

12 December 2020

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

12 December 2020

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

12 December 2020

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

12 December 2020

Therapy of metastatic bone pain

1 reference

12 December 2020

A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease

1 reference

12 December 2020

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

12 December 2020

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

12 December 2020

Estimating the world cancer burden: Globocan 2000.

1 reference

12 December 2020

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints

1 reference

12 December 2020

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

12 December 2020

Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease

1 reference

12 December 2020

Bisphosphonate actions on cancer

1 reference

12 December 2020

Percutaneous vertebroplasty: indications, contraindications, and technique

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

12 December 2020

Radiotherapy-related fatigue

1 reference

12 December 2020

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

12 December 2020

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

1 reference

12 December 2020

Bisphosphonate therapy in the oncology setting

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

12 December 2020

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Effectiveness and cost of bisphosphonate therapy in tumor bone disease

1 reference

12 December 2020

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis

1 reference

12 December 2020

Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial

1 reference

12 December 2020

10.1007/S11864-005-0023-0

Identifiers

DOI

1 reference

11 August 2017

1 reference